iTOL-200 and iTOL-201

Developing a Potential Treatment for Liver Failure

Treatment of liver failure through a liver transplant utilizing human hepatocytes without the need for chronic immunosuppression to prevent graft rejection would be a major advance in the liver transplantation field. iTOL-200 is based on the same concept as iTOL-100 except with a smaller microgel size (50 micron microgel).  iTOL-200 will be tested when co-administered with LyGenesis’ liver cell therapy (LYG-LIV-100), to form iTOL-201 with the potential to enable ectopic livers to be implanted without the need for immune suppression.  Early in vitro data with SA-FasL microgels co-administered with hepatocytes  showed no significant impact of survival of hepatocytes.  Next steps are to evaluate iTOL-201 in a preclinical animal model of liver transplantation.